Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Medtech Matters

Medtech Matters artwork

You Got a 483 from the FDA. Now what?

Aug 22, 202459 minAudio
ShareXLinkedInFacebookWhatsAppEmail

In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re discussing what the process should be for a company once they receive a 483 or warning letter from the FDA. Best practices, first steps to take, who is responsible, and potential strategies for avoiding them are shared. Specifically, the following questions are addressed: Could you please explain what a 483 is and what a warning letter is? Are they the same thing? What are some common reasons or examples of why a company would get a 483 or warning letter? What are the first steps for a company that has just received a warning letter or 483? Who is responsible for the response to a 483 or warning letter? Does this fall to regulatory? Quality? Who really should be responsible for addressing it? Is it common for a company to get a warning letter or 483 for the same issue? If that happens, what then should the company do? What’s worse than a 483 or warning letter? Is there a higher level that really causes a concern for the company involved? What should be considered in terms of the PR hit as a result of a 483 or warning letter? Do you have suggestions with regard to preventing a 483 or warning letter? Anything more a company should consider and after that, please share what you consider to be the most important takeaways? Listen to this discussion and see if you have a better handle on what to do if you get a 483 or warning letter. If you’d like to share thoughts, ask questions, or have a suggestion for a future topic for us to cover, please reach out to me at sfenske@rodmanmedia.com and we’ll see if we want to address your ideas/inquiries/suggestions in a future episode. Send us Fan Mail For more medtech news and information, visit https://www.mpomag.com.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. An Early Look at FDA’s Guidance Focus for 2027, Part 2

    Nov 2, 20261 hr 2 minAudio

    In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re continuing the conversation of guidance documents that are expected to gain the attention of the agency...

    Credit the people on this episode

  2. An Early Look at FDA’s Guidance Focus for 2027, Part 1

    Nov 2, 202647 minAudio

    In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we review the list of guidances FDA expects to begin to focus on in 2027. The list really represents the...

    Credit the people on this episode

  3. A Preview of MDUFA VI: Changes and Highlights, Part 2

    Sep 11, 202650 minAudio

    In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re into part 2 of the discussion in an early look at the next Medical Device User Fee Act, MDUFA VI, which...

    Credit the people on this episode

  4. A Preview of MDUFA VI: Changes and Highlights, Part 1

    Sep 11, 202648 minAudio

    In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re taking an early look at the next version of the Medical Device User Fee Act, MDUFA VI, which would go...

    Credit the people on this episode

  5. The Value in Partnering for Sterility Testing

    Sep 9, 202626 minAudio

    In this Medtech Matters podcast episode, sponsored by Nelson Labs, two representatives from the company offer their expertise and insights on sterility testing. Amina Rahmoune, Laboratory Operations Manager - Sterility...

    Credit the people on this episode